Planta Med 2011; 77 - P_31
DOI: 10.1055/s-0031-1273560

Chiratane Triterpenoid from the Rhizomes of Drynaria fortunei

YH Liang 1, W Wang 3, M Ye 1, IA Khan 3, 4, 5, DA Guo 1, 2
  • 1The State Key Laboratory of Natural and Biomimetic Drugs, School of Pharmaceutical Sciences, Peking University, Beijing 100191, P. R. China
  • 2Shanghai Research Center for Modernization of TCM, Shanghai Institute of Materia Medica, CAS, Guo Shoujing Road 199, Shanghai 201203, P. R. China
  • 3National Center for Natural Products Research, School of Pharmacy, The University of Mississippi, University, MS 38677, USA
  • 4Department of Pharmacognosy, Research Institute of Pharmaceutical Sciences, School of Pharmacy, The University of Mississippi, University, MS 38677, USA
  • 5Department of Pharmacognosy, College of Pharmacy, King Saud University, Riyadh, Saudi Arabia

Drynaria fortunei (Kunze) J. Sm. (Polypodiaceae) is a fern indigenous to China. Its rhizomes named „Gu Sui Bu“, have been widely used for the treatment of osteoporosis and bone fracture as a famous Traditional Chinese Medicine [1]. Previous phytochemical investigations reported the isolation of some triterpenoids and flavonoids from D. fortunei [2–3]. Like most ferns, D. fortunei is abundant in triterpenoids, most of which are of the hopane and fernane skeletons. Our ongoing phytochemical study of D. fortunei resulted in the isolation of a new chiratane type triterpenoid chiratone (1), together with five known hopane titerpenoids, namely, fern-9(11)-ene, dryocrassol acetate, hop-22(29)-ene, dryocrassol, and isoglaucanone. Their cytotoxicities were evaluated. Compound 1 possessed significant cytotoxic activity against Hela, PC3 and Hep G2 cells, with IC50 of 2.92µM, 1.08µM and 2.45µM, respectively.

Acknowledgements: This work was supported by the program for Changjiang Scholars and Innovation Team in University (No. 985–2-063–112) and the „985“ Project of Peking University Health Science Center (No. 985–2-119–121).

References: [1] Pharmacopoeia of China, Part 1. Beijing: Chemical Industry Press, 2005:179. [2] Chang EJ, Lee WJ, et al. (2003) Arch Pharm Res, 26: 620–630. [3] Zhou TS, Zhou RH (1994) Zhongcaoyao, 25: 175–178.